Video

Dr Melinda Magyari Explains the Treatment Landscape for Pediatric-Onset MS

Melinda Magyari, MD, PhD, consultant neurologist, the Danish Multiple Sclerosis Center, Copenhagen University Hospital, explains the treatment paradigm for pediatric-onset multiple sclerosis (MS).

Melinda Magyari, MD, PhD, consultant neurologist, the Danish Multiple Sclerosis Center, Copenhagen University Hospital, explains the treatment paradigm for pediatric-onset multiple sclerosis (MS).

Transcript

What does the treatment paradigm for pediatric MS look like today?

That's a good question, but we have the recommendation from the international multiple sclerosis group that disease-modifying treatment should be initiated in children with MS. Of course, the benefit/risk should be also taken into consideration, so the treatment paradigm in most of the countries is escalation therapy, starting with a mild, moderately effective drug in mild and moderate diseases activity. But I see in our registry and also in others that children with highly active disease are initiated with more effective therapies.

Related Videos
Frederick L Locke, MD, Moffitt
Sam Peasah, PhD, MBA, RPh, director for the Center of High-Value Health Care at the University of Pittsburgh Medical Center (UPMC)
Pierluigi Porcu, MD
Benjamin Chen, MD, PhD
Kimberly Westrich, MA, chief strategy officer, NPC
Erin Weber, MS
JC Scott, CEO and president of The Pharmaceutical Care Management Association (PCMA)
Marla Black Morgan, MD, Phoebe Neurology Associates
Elizabeth Grush, MBA
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo